Alder BioPharmaceuticals, a company bringing new therapies to the treatment of migraines, rheumatoid arthritis and other conditions, priced its IPO at $10 per share, well below its proposed $13 to $15 range, and went public, raising $80 million. It is trading on the NASDAQ under the symbol ALDR. Alder previously raised $40.2 million of Series C funding at a $105 million valuation in 2008. More recently, the company raised $38 million of Series D funding in 2012. Its investors include Sevin Rosen Funds (23.7% pre-IPO stake), Ventures West Capital (14.7%), Novo A/S (12.1%), H.I.G. BioVentures (11.8%), TPG Biotech (11.4%) and Delphi Ventures (11.4%).